Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian
July 10, 2024 08:05 ET
|
Tevogen Bio Inc
Dr. Flomenberg and Dr. Grosso are leading experts in T cell biology and its clinical applicationsTevogen’s ExacTcell™ platform is designed to address current cost, and patient accessibility...
Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024
July 08, 2024 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development
July 08, 2024 02:00 ET
|
Myricx Bio
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and AbingworthAdditional new investors British Patient Capital, Cancer Research Horizons and Lilly participated...
Global Continuing Medical Education Market to Reach USD 18.45 billion by 2032, Experiencing Steady Growth at a 7.72% CAGR | Straits Research
July 04, 2024 09:35 ET
|
Straits Research Private Limited - Garner Insights
New York, United States, July 04, 2024 (GLOBE NEWSWIRE) -- As per the latest report by Straits Research, the global continuing medical education market size was valued at USD 9.45 billion in 2023....
ICPO Foundation kooperiert mit Nuclear Medicine Research Infrastructure (NuMeRI), um ein ICPO Collaborating Center zu etablieren
July 04, 2024 00:00 ET
|
ICPO Foundation
Diese Zusammenarbeit verbessert die globalen Bildungsstandards in der Radiotheranostik und zielt darauf ab, den Zugang der Patienten zu einer neuen Ära effektiver Krebstherapien in Südafrika zu...
ICPO Foundation partners with Nuclear Medicine Research Infrastructure (NuMeRI) to establish an ICPO Collaborating Center
July 04, 2024 00:00 ET
|
ICPO Foundation
This collaboration enhances global educational benchmarks in radiotheranostics and aims to expand patient access to a new era of effective cancer therapeutics in South Africa. July 4, 2024 –...
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
July 03, 2024 08:55 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., July 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the next CEO Corner segment has been published on the Company’s...
Cross Keys Capital Advises New Jersey Cancer Care, PA, in Its Partnership with Regional Cancer Care Associates
July 02, 2024 08:00 ET
|
Cross Keys Capital, LLC.
Fort Lauderdale, July 02, 2024 (GLOBE NEWSWIRE) -- Cross Keys Capital, LLC, a leading independent investment banking firm providing M&A advisory services to physician group practices and...
Global Cancer Diagnostics Market Size To Exceed USD 323.17 Billion By 2033 | CAGR of 8.71%
July 01, 2024 20:00 ET
|
SPHERICAL INSIGHTS LLP
New York, United States , July 01, 2024 (GLOBE NEWSWIRE) -- The Global Cancer Diagnostics Market Size is to Grow from USD 140.25 Billion in 2023 to USD 323.17 Billion by 2033, at a CAGR of 8.71%...
Nipocalimab pivotal Phase 3 trial demonstrates sustained disease control in FcRn class for a broad population of myasthenia gravis patients
June 28, 2024 12:09 ET
|
Janssen Cilag International NV
First FcRn blocker to demonstrate superiority in Myasthenia Gravis - Activities of Daily Living score (MG-ADL) a over placebo when added to standard of care over 24 weeks in antibody positive...